Cite
HARVARD Citation
McLaughlin, P. et al. (2023). Rituximab Chimeric Anti-CD20 Monoclonal Antibody Therapy for Relapsed Indolent Lymphoma: Half of Patients Respond to a Four-Dose Treatment Program. Journal of clinical oncology. 41 (2), pp. 154-162. [Online].